Pharvaris Yönetim

Yönetim kriter kontrolleri 3/4

Pharvaris CEO'su Berndt Axel Modig, Sep2015 tarihinde atandı, in görev süresi 9.17 yıldır. in toplam yıllık tazminatı € 532.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.77% ine doğrudan sahiptir ve bu hisseler $ 35.65M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3.8 yıldır.

Anahtar bilgiler

Berndt Axel Modig

İcra Kurulu Başkanı

€532.0k

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	9.2yrs
CEO sahipliği	2.8%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Berndt Axel Modig'un ücretlendirmesi Pharvaris'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-€132m
Jun 30 2024	n/a	n/a	-€114m
Mar 31 2024	n/a	n/a	-€106m
Dec 31 2023	€532k	€532k	-€101m
Sep 30 2023	n/a	n/a	-€107m
Jun 30 2023	n/a	n/a	-€92m
Mar 31 2023	n/a	n/a	-€83m
Dec 31 2022	€500k	€500k	-€76m
Sep 30 2022	n/a	n/a	-€49m
Jun 30 2022	n/a	n/a	-€50m
Mar 31 2022	n/a	n/a	-€53m
Dec 31 2021	€414k	€414k	-€43m
Sep 30 2021	n/a	n/a	-€41m
Jun 30 2021	n/a	n/a	-€38m
Mar 31 2021	n/a	n/a	-€29m
Dec 31 2020	€404k	€404k	-€26m

Tazminat ve Piyasa: Berndt Axel 'nin toplam tazminatı ($USD 557.36K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.57M ).

Tazminat ve Kazançlar: Berndt Axel şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Berndt Axel Modig (65 yo)

9.2yrs

Görev süresi

€532,000

Tazminat

Mr. Berndt Axel Edvard Modig, MBA, CPA, serves as Chief Executive Officer since 2015 and Executive Director of Pharvaris B.V. Mr. Modig served as a Member of the Supervisory Board at Centogene N.V. since A...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Berndt Axel Modig	Co-Founder	9.2yrs	€532.00k	2.77% $ 35.6m
Anna Nijdam	Head of Strategic Finance & Principal Accounting Officer	no data	Veri yok	0.093% $ 1.2m
Stefan Abele	Chief Technology Operations Officer	less than a year	Veri yok	Veri yok
Annick Deschoolmeester	Chief Human Resources Officer	2.2yrs	Veri yok	0.033% $ 422.7k
Peng Lu	Chief Medical Officer	4.8yrs	Veri yok	0.84% $ 10.8m
Anne Lesage	Chief Early Development Officer	no data	Veri yok	0.92% $ 11.9m
Wim Souverijns	Chief Commercial Officer	3.3yrs	Veri yok	0.20% $ 2.6m
David Nassif	CFO & Corporate Secretary	less than a year	Veri yok	Veri yok
Maryann Cimino	Director of Corporate Relations	no data	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: PHVS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Berndt Axel Modig	Co-Founder	no data	€532.00k	2.77% $ 35.6m
Robert Glassman	Independent Non-Executive Director	3.8yrs	€50.50k	0.061% $ 790.1k
David Meeker	Independent Non-Executive Chair	3.8yrs	€94.00k	0.22% $ 2.9m
Hans J. G. C. Schikan	Independent Vice Chairman	5.3yrs	€61.00k	0.93% $ 12.0m
Elisabeth Bjork	Non-Executive Director	2.9yrs	€45.00k	0.041% $ 523.4k
Viviane Monges	Non-Executive Director	3.3yrs	€62.50k	0.058% $ 751.5k

3.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PHVS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Pharvaris Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Recent updates

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat